Ensure you have read through the FDA's IDE Approval Process webpage:
https://www.fda.gov/medical-devices/investigational-device-exemption-ide/ide-approval-process
Then, I suggest reading through this guidance to be sure you understand the connection to what you'll need to send to your Institutional Review Board (IRB) as they will want to see your rationale for the study being a nonsignificant risk (NSR) study.
FDA Guidance Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Significant Risk and Nonsignificant Risk Medical Device Studies
https://www.fda.gov/media/75459/download
If the IRB agrees with the NSR determination, then the 'abbreviated IDE' content is all the records that the manufacturer (you) need to keep in support of the study and the safety of the participants. The IRB will want to see, at minimum, the labeling, and the informed consent. It's best to work with them to agree upon the content as different IRB's can require different content. Also, I've seen some IRB's not support NSR studies without some interaction with FDA to agree that the study is indeed NSR.
------------------------------
Isabel McGann MS, RAC
Regulatory Program Manager
Westminster, CO
United States
------------------------------
Original Message:
Sent: 12-Oct-2021 14:40
From: Anonymous Member
Subject: Abbreviated IDE
This message was posted by a user wishing to remain anonymous
We currently have a protocol for a non-significant risk device that the sponsor-investigator would like to commercialize and bring to market pending the results of the study and if it is found to be effective. They already have a patent pending on the product. They haven't initiated the study yet. I believe this would fall under the category of an abbreviated IDE but have never submitted one in my career. Would an abbreviated IDE be submitted to the FDA like a full IDE?